Klin Farmakol Farm. 2025;39(1):14-21 | DOI: 10.36290/far.2025.017

Lipid lowering with inclisiran: a single-center experience from Slovakia

Stefan Toth1, Marianna Barbierik Vachalcova2, Adriana Jarolimkova1, Martin Sevcik3, Tibor Poruban2
1 Gerontology and Geriatrics Clinic and School of Medicine, Pavol Jozef Safarik University, Kosice, Slovakia
2 East Slovak Institute of Cardiovascular Diseases and School of Medicine, Pavol Jozef Safarik University, Kosice, Slovakia
3 Department of Infectious diseases, Faculty hospital of Jan Adam Rayman, Presov, Slovakia

Background: Inhibiting proprotein convertase subtilisin/kexin type 9 activity is an effective strategy to lower LDL cholesterol (LDL-C), a major cardiovascular risk factor. Inclisiran, the first small interfering RNA targeting PCSK9, has shown a 50% LDL-C reduction in clinical trials.

Aims: The aim of this study was to describe the effects of inclisiran in real-world clinical settings, along with the first clinical experiences of its use in Slovakia.

Methods: In this observational study, 36 patients were selected for inclisiran therapy as part of standard clinical assessments, procedures, and reimbursement from public health insurance. Each patient underwent a standard lipid profile assessment and high-sensitivity C-reactive protein (hsCRP) testing before submitting applications for therapy approval, and again one month after receiving two doses of inclisiran. The average change in lipid profile levels was calculated for each patient who completed the third dose of inclisiran.

Results: Inclisiran therapy was approved for 36 patients, including 27 with athero­sclerotic coronary artery disease and 9 with prior strokes. The cohort included 1 statin-intolerant patient, 28 on maximum statin doses, and 7 on reduced doses. After 3 months, LDL-C dropped by 57.5 %, hsCRP to 1.2 mg/dL, and lipoprotein(a) by 14.3 ± 6.4 %. Safety outcomes mirrored clinical trials, with mild injection-site pain in 26 cases and flu-like symptoms in 3.

Conclusions: Inclisiran demonstrated an effective reduction in LDL-C and hsCRP levels, slightly exceeding clinical trial outcomes, but lipoprotein(a) reductions varied among patients. Safety was consistent with expectations, confirming inclisiran‘s potential for broader clinical use.

Keywords: inclisiran, LDL-C, hsCRP, lipoprotein(a), target values

Accepted: April 15, 2025; Published: April 29, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Toth S, Barbierik Vachalcova M, Jarolimkova A, Sevcik M, Poruban T. Lipid lowering with inclisiran: a single-center experience from Slovakia. Klin Farmakol Farm. 2025;39(1):14-21. doi: 10.36290/far.2025.017.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Vardas P, Townsend N, Torbica A, et al. European Society of Cardiology: cardiovascular disease statistics 2021. Eur Heart J. 2022;43(8):716-799. Go to original source... Go to PubMed...
    2. Štatistický úrad SR. Najčastejšie príčiny úmrtia obyvateľov SR [Internet]. 2023 [cited 25-01-02]. Available from: https://statdat.statistics.sk/.
    3. Český statistický úřad. Smrt v datech [Internet]. 2023 [cited 25-01-02]. Available from: https://statistikaamy.csu.gov.cz/.
    4. Baigent C, Blackwell L, Emberson J, et al. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670-1681. Go to original source... Go to PubMed...
    5. Nicholls SJ, Kataoka Y, Nissen SE, et al. Effect of evolocumab on coronary plaque phenotype and burden in statin-treated patients following myocardial infarction. JACC Cardiovasc Imaging. 2022;15(7):1308-1321. Go to original source... Go to PubMed...
    6. Khvorova A. Oligonucleotide Therapeutics - A New Class of Cholesterol-Lowering Drugs. N Engl J Med. 2017;376(1):4-7. Go to original source... Go to PubMed...
    7. Raal FJ, Kallend D, Ray KK, et al. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. N Engl J Med. 2020;382(16):1520-1530. Go to original source... Go to PubMed...
    8. Alonso R, Arroyo-Olivares R, Muñiz-Grijalvo O, et al. Persistence with long-term PCSK9 inhibitor treatment and its effectiveness in familial hypercholesterolaemia: data from the SAFEHEART study. Eur J Prev Cardiol. 2023;30(4):320-328. Go to original source... Go to PubMed...
    9. A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Cardiovascular Disease (ORION-4). Available from: https://clinicaltrials.gov/ct2/show/NCT03705234. Accessed: November 16, 2024.
    10. Ray KK, Stoekenbroek RM, Kallend D, et al. Effect of 1 or 2 doses of inclisiran on low-density lipoprotein cholesterol levels: one-year follow-up of the ORION-1 randomized clinical trial. JAMA Cardiol. 2019;4(11):1067-1075. Go to original source... Go to PubMed...
    11. Ray KK, Troquay RP, Visseren FI, et al. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial. Lancet Diabetes Endocrinol. 2023;11:109-119. Go to original source... Go to PubMed...
    12. Raal FJ, Kallend D, Ray KK, et al. Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N Engl J Med. 2020;382(16):1520-1530. Go to original source... Go to PubMed...
    13. Katsiki N, Vrablik M, Banach M, et al. Inclisiran, low-density lipoprotein cholesterol and lipoprotein (a). Pharmaceuticals (Basel). 2023;16(4):577. Go to original source... Go to PubMed...
    14. Padam P, Barton L, Wilson S, et al. Lipid lowering with inclisiran: a real-world single-centre experience. Open Heart. 2022;9(2):e002184. Go to original source... Go to PubMed...
    15. Basile C, Gargiulo P, Merlini PA, et al. Efficacy and safety of inclisiran in real-world practice: insights from the Cholinet registry. Eur Heart J. 2023;44(Suppl 2):ehad655-2812. Go to original source...
    16. Wright RS, Raal FJ, Koenig W, et al. Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial. Cardiovasc Res. 2024; 120(12):1400-1410. Go to original source... Go to PubMed...
    17. Makhmudova U, Schatz U, Perakakis N, et al. High interindividual variability in LDL-cholesterol reductions after inclisiran administration in a real-world multicenter setting in Germany. Clin Res Cardiol. 2023;112(11):1639-1649. Go to original source... Go to PubMed...
    18. Mulder JWCM, Galema-Boers AMH, Roeters van Lennep JE. First clinical experiences with inclisiran in a real-world setting. J Clin Lipidol. 2023;17(6):818-827. Go to original source... Go to PubMed...
    19. Lagace TA. PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells. Curr Opin Lipidol. 2014;25(5):387-393. Go to original source... Go to PubMed...
    20. Dong B, Wu M, Li H, et al. Strong induction of PCSK9 gene expression through HNF1alpha and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters. J Lipid Res. 2010;51(6):1486-1495. Go to original source... Go to PubMed...
    21. Bao X, Liang Y, Chang H, et al. Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside. Signal Transduct Target Ther. 2024;9(1):13. Go to original source... Go to PubMed...
    22. Patnaik S, Pollevick ME, Lara-Breitinger KM, et al. Inter-individual variability in lipid response: a narrative review. Am J Med. 2022;135(12):1427-1433.e7. Go to original source... Go to PubMed...
    23. Ray KK, Bruckert E, Peronne-Filardi P, et al. Long-term persistence with evolocumab treatment and sustained reductions in LDL-cholesterol levels over 30 months: final results from the European observational HEYMANS study. Atherosclerosis. 2023;366:14-21. Go to original source... Go to PubMed...
    24. Vonbank A, Drexel H, Agewall S, et al. Reasons for disparity in statin adherence rates between clinical trials and real-world observations: a review. Eur Heart J Cardiovasc Pharmacother. 2018;4(4):230-236. Go to original source... Go to PubMed...
    25. Arnold N, Koenig W. PCSK9 Inhibitor Wars: How Does Inclisiran Fit in with Current Monoclonal Antibody Inhibitor Therapy? Considerations for Patient Selection. Curr Cardiol Rep. 2022;24(11):1657-1667. Go to original source... Go to PubMed...
    26. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713-1722. Go to original source... Go to PubMed...
    27. Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097-2107. Go to original source... Go to PubMed...
    28. Bittner VA, Schwartz GG, Bhatt DL, et al. Alirocumab and cardiovascular outcomes according to sex and lipoprotein(a) after acute coronary syndrome: a report from the ODYSSEY OUTCOMES study. J Clin Lipidol. 2024;18(4):e548-e561. Go to original source... Go to PubMed...
    29. Ying Q, Chan DC, Watts GF. New Insights Into the Regulation of Lipoprotein Metabolism by PCSK9: Lessons From Stable Isotope Tracer Studies in Human Subjects. Front Phy­siol. 2021;12:603910. Go to original source... Go to PubMed...
    30. Libby P, Ridker PM. Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am J Med. 2004; 116(Suppl 6A):S9-S16. Go to original source... Go to PubMed...
    31. Landmesser U, Conde LG, Wright RS, et al. Effect of inclisiran on haematological and immunological biomarkers: a pooled analysis of ORION-9, -10, and -11 trial data. Atherosclerosis. 2021;331:E37. Go to original source...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.